Literature DB >> 27473102

Type 1 familial partial lipodystrophy: understanding the Köbberling syndrome.

Cristina Guillín-Amarelle1,2, Sofía Sánchez-Iglesias1, Ana Castro-Pais2,3, Leticia Rodriguez-Cañete1,2, Lucía Ordóñez-Mayán2,3, Marcos Pazos2,3, Blanca González-Méndez1, Silvia Rodríguez-García1, Felipe F Casanueva2,3, Ana Fernández-Marmiesse4, David Araújo-Vilar5,6.   

Abstract

Familial partial lipodystrophy are Mendelian disorders involving abnormal body fat distribution and insulin resistance. The current classification includes the Köbberling syndrome (type 1 familial partial lipodystrophy), characterized by fat loss in the lower limbs and abnormal fat accumulation in other areas. Type 1 familial partial lipodystrophy appears to be heritable, but little is known about it, including putative contributing mutations. We aimed to characterize this syndrome better by evaluating a group of women with phenotypic features of type 1 familial partial lipodystrophy. This is a case-controlled study in which 98 women with type 1 familial partial lipodystrophy that lacked classical mutations known to cause familial partial lipodystrophy were compared with 60 women without lipodystrophy and 25 patients with type 2 familial partial lipodystrophy (Dunnigan disease). Clinical course, body composition by dual-energy X-ray absorptiometry, HbA1c, lipid profile, insulin, leptin and family history were evaluated in all of the participants. Analyses of receiver-operating characteristic curve were performed for type 1 familial partial lipodystrophy diagnosis, comparing different truncal/limbs ratios. Among patients with type 1 familial partial lipodystrophy, 68 % developed recognizable lipodystrophy before adolescence, and most displayed an autosomal-dominant pattern (86 %). Women with type 1 familial partial lipodystrophy had less lower-limb adipose tissue than women without lipodystrophy, but significantly more than patients with Dunnigan disease. Moreover, metabolic disturbances occurred more frequently in the type 1 familial partial lipodystrophy group (81 %) than in the non-lipodystrophic group (30 %, p<0.05). The severity of metabolic disturbances was inversely proportional to the percentage of fat in the lower extremities and directly proportional to the amount of visceral adipose tissue. Metabolic profiles were worse in type 1 familial partial lipodystrophy than in Dunnigan disease. According to the receiver-operating characteristic curve analysis, the best ratio was subscapular/calf skinfolds (KöB index), with a cut-off value of 3.477 (sensitivity: 89 %; specificity: 84 %). Type 1 familial partial lipodystrophy was an early-onset, autosomal-dominant lipodystrophy, characterized by fat loss in the lower limbs and abnormal fat accumulation in the abdominal visceral region, associated to insulin resistance and metabolic disorders. A KöB index >3.477 is highly suggestive of this syndrome.

Entities:  

Keywords:  Body composition; Familial partial lipodystrophy; Visceral adipose tissue

Mesh:

Substances:

Year:  2016        PMID: 27473102     DOI: 10.1007/s12020-016-1002-x

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  26 in total

1.  Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy.

Authors:  H Cao; R A Hegele
Journal:  Hum Mol Genet       Date:  2000-01-01       Impact factor: 6.150

2.  Correct homeostasis model assessment (HOMA) evaluation uses the computer program.

Authors:  J C Levy; D R Matthews; M P Hermans
Journal:  Diabetes Care       Date:  1998-12       Impact factor: 19.112

3.  Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.

Authors:  I Barroso; M Gurnell; V E Crowley; M Agostini; J W Schwabe; M A Soos; G L Maslen; T D Williams; H Lewis; A J Schafer; V K Chatterjee; S O'Rahilly
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

4.  Familial lipoatrophic diabetes with dominant transmission. A new syndrome.

Authors:  M G Dunnigan; M A Cochrane; A Kelly; J W Scott
Journal:  Q J Med       Date:  1974-01

5.  Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Leonelo Bautista; Maria Grazia Franzosi; Patrick Commerford; Chim C Lang; Zvonko Rumboldt; Churchill L Onen; Liu Lisheng; Supachai Tanomsup; Paul Wangai; Fahad Razak; Arya M Sharma; Sonia S Anand
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

6.  Estimating intraabdominal adipose tissue in women by dual-energy X-ray absorptiometry.

Authors:  M S Treuth; G R Hunter; T Kekes-Szabo
Journal:  Am J Clin Nutr       Date:  1995-09       Impact factor: 7.045

7.  Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety).

Authors:  A Garg
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

Review 8.  Etiological investigations in apparent type 2 diabetes: when to search for lamin A/C mutations?

Authors:  B Donadille; O Lascols; J Capeau; C Vigouroux
Journal:  Diabetes Metab       Date:  2005-12       Impact factor: 6.041

9.  Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study.

Authors:  Marieke B Snijder; Jacqueline M Dekker; Marjolein Visser; Lex M Bouter; Coen D A Stehouwer; Piet J Kostense; John S Yudkin; Robert J Heine; Giel Nijpels; Jacob C Seidell
Journal:  Am J Clin Nutr       Date:  2003-05       Impact factor: 7.045

10.  Analysis of genetic variation in Akt2/PKB-beta in severe insulin resistance, lipodystrophy, type 2 diabetes, and related metabolic phenotypes.

Authors:  Karen Tan; Wendy A Kimber; Jian'an Luan; Maria A Soos; Robert K Semple; Nicholas J Wareham; Stephen O'Rahilly; Inês Barroso
Journal:  Diabetes       Date:  2007-03       Impact factor: 9.461

View more
  11 in total

1.  Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort.

Authors:  Nevin Ajluni; Rasimcan Meral; Adam H Neidert; Graham F Brady; Eric Buras; Barbara McKenna; Frank DiPaola; Thomas L Chenevert; Jeffrey F Horowitz; Colleen Buggs-Saxton; Amit R Rupani; Peedikayil E Thomas; Marwan K Tayeh; Jeffrey W Innis; M Bishr Omary; Hari Conjeevaram; Elif A Oral
Journal:  Clin Endocrinol (Oxf)       Date:  2017-03-27       Impact factor: 3.478

2.  "Fat Shadows" From DXA for the Qualitative Assessment of Lipodystrophy: When a Picture Is Worth a Thousand Numbers.

Authors:  Rasimcan Meral; Benjamin J Ryan; Noemi Malandrino; Abdelwahab Jalal; Adam H Neidert; Ranganath Muniyappa; Barış Akıncı; Jeffrey F Horowitz; Rebecca J Brown; Elif A Oral
Journal:  Diabetes Care       Date:  2018-10       Impact factor: 19.112

3.  Approach to the Patient With Lipodystrophy.

Authors:  Lindsay T Fourman; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2022-05-17       Impact factor: 6.134

Review 4.  Severe insulin resistance syndromes.

Authors:  Angeliki M Angelidi; Andreas Filippaios; Christos S Mantzoros
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

Review 5.  Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People

Authors:  Samim Özen; Barış Akıncı; Elif A. Oral
Journal:  J Clin Res Pediatr Endocrinol       Date:  2019-08-22

6.  Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy.

Authors:  Elif A Oral; Phillip Gorden; Elaine Cochran; David Araújo-Vilar; David B Savage; Alison Long; Gregory Fine; Taylor Salinardi; Rebecca J Brown
Journal:  Endocrine       Date:  2019-02-25       Impact factor: 3.633

Review 7.  Lipodystrophic laminopathies: Diagnostic clues.

Authors:  Cristina Guillín-Amarelle; Antía Fernández-Pombo; Sofía Sánchez-Iglesias; David Araújo-Vilar
Journal:  Nucleus       Date:  2018-01-01       Impact factor: 4.197

8.  Clinical Characteristics, Phenotype of Lipodystrophy and a Genetic Analysis of Six Diabetic Japanese Women with Familial Partial Lipodystrophy in a Diabetic Outpatient Clinic.

Authors:  Masanori Iwanishi; Jun Ito-Kobayashi; Miki Washiyama; Toru Kusakabe; Ken Ebihara
Journal:  Intern Med       Date:  2018-03-30       Impact factor: 1.271

Review 9.  A Comprehensive Update on the Chylomicronemia Syndrome.

Authors:  Ronald B Goldberg; Alan Chait
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-23       Impact factor: 5.555

10.  Observation of p.R4810K, a Polymorphism of the Mysterin Gene, the Susceptibility Gene for Moyamoya Disease, in Two Female Japanese Diabetic Patients with Familial Partial Lipodystrophy 1.

Authors:  Masanori Iwanishi; Choka Azuma; Yuji Tezuka; Yukako Yamamoto; Jun Ito-Kobayashi; Miki Washiyama; Toru Kusakabe; Shingo Kikugawa
Journal:  Intern Med       Date:  2020-10-15       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.